溶小體貯積症治療市場－全球產業規模、佔有率、趨勢、機會、預測：治療方法、適應症、終端用戶、地區及競爭格局，2021-2031年

全球溶小體貯積症治療市場預計將從 2025 年的 76.9 億美元成長到 2031 年的 117.2 億美元，複合年成長率為 7.28%。

這些療法包括一些特定的醫療干預措施，例如酵素替代療法和基材減少療法，旨在糾正溶酶體功能障礙導致的代謝異常。這項市場擴張主要得益於診斷能力的進步，包括新生兒篩檢，以及公共和私人機構對孤兒藥研究的大量投資。例如，美國國立衛生研究院 (NIH) 已為罕見疾病臨床研究網路在 2025 財政年度津貼約 2,600 萬美元，這表明其對推進這些疾病的臨床研究做出了重大的財務承諾。

儘管取得了這些進展，但市場成長的主要障礙仍然是藥物研發成本極高，由此帶來的定價壓力。此外，複雜的法規環境，以及由於患者群體規模小且地域分散而難以招募足夠的臨床試驗參與者，都對新療法的市場推廣構成了重大阻礙。

市場促進因素

酵素替代療法和基因療法的進步正在從根本上改變溶酶體貯積症治療的全球市場，將臨床重點從單純的症狀治療轉向標靶緩解疾病。創新生物製藥採用改良的細胞內攝取機制，能夠更有效地解決這些複雜疾病的潛在代謝異常，進而促進其商業性化應用。這些新一代治療方法的商業性影響力在專業產品系列的快速成長中得到了清晰體現。例如，凱西集團罕見疾病業務部門在2025年上半年實現了31.4%的成長率，凸顯了市場對其先進治療方案的強勁需求。

同時，支持性孤兒藥政策和監管獎勵在維持針對這些小眾適應症的高風險開發平臺發揮著至關重要的作用。政府提供的市場獨佔權和快速核准流程等項目，為投資於針對特定患者群體治療方法的生物製藥公司提供了必要的財務保障。此支持體系的有效性體現在監管核准記錄：2024年，FDA核准的新藥中有52%被指定用於治療罕見疾病。這種政策主導的環境與商業性永續性直接相關。例如，Amicus Therapeutics公司報告稱，其2025年第三季的總銷售額為1.691億美元，凸顯了精準醫療在該領域持續的財務可行性。

市場挑戰

藥物研發成本高昂，加上臨床試驗招募受試者數量本身就十分困難，這些都嚴重限制了溶小體儲積症治療藥物的全球市場發展。由於企業面臨更長的研發週期，以及在地域分散、患者群體規模較小的情況下驗證藥物安全性和有效性的成本不斷增加，這些財務和後勤方面的障礙導致新治療方法的研發失敗率居高不下。這種高風險環境往往會抑制企業對除最具商業性前景的候選藥物之外的其他藥物的持續投資，從而導致潛在治療方法的研發管線變窄，並減緩市場整體擴張的速度。

這些障礙的後果在已確診的代謝性疾病與現有醫療干預措施之間存在的巨大差距中得到了清晰的體現。根據美國國家罕見疾病組織（NORD）預測，到2025年，超過95%的罕見疾病仍缺乏FDA核准的治療方法。這項數據凸顯了挑戰的嚴峻性。即使診斷能力提高，研發的經濟負擔也常常阻礙絕大多數罕見疾病治療方法的商業化，從而限制了該領域的收入成長和市場成熟度。

市場趨勢

口服基材減少療法的顯著轉變正在改變治療現狀，它為終身靜脈輸注提供了一種非侵入性的替代方案。這種趨勢透過便捷的口服給藥方式抑制毒性基材的積累，從而減輕了患者的負擔，而無需完全依賴全身性酵素替代療法。該治療方法的商業性吸引力極高。例如，賽諾菲公司報告稱，其口服藥物「Selderga」在2024年第三季的銷售額達到8,100萬歐元，這凸顯了市場對以患者為中心的給藥機制的持續需求，尤其是在高雪氏症領域。

在罕見疾病這一高風險領域，孤兒藥研發管線的策略整合正成為確保財務永續性的關鍵機制。生物製藥公司正日益建構多元化的產品組合，涵蓋已上市產品和處於後期臨床試驗階段的候選藥物，以降低單一產品依賴性帶來的波動風險。這種多元化策略帶來了切實的穩定性。例如，Ultragenyx公司在2024年第三季實現了1.39億美元的總收入，充分展現了其專注於多種罕見代謝疾病適應症的整合平台所蘊含的經濟實力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：溶小體貯積症治療藥物的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（酵素替代療法、幹細胞療法、基材減少療法等）
  • 適應症（高雪氏症、法布瑞氏症、龐貝氏症、黏多醣症症等）
  • 依最終用戶（醫院、診所）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美溶小體貯積症治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲溶小體貯積症治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區溶小體貯積症治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲溶小體貯積症治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲溶小體貯積症治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：溶小體貯積症治療藥物的全球市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer, Inc.
• Sanofi SA
• BioMarin Pharmaceutical Inc
• Actelion Ltd.
• Raptor Pharmaceutical Corp.
• Protalix Biotherapeutics Inc.
• Amicus Therapeutics, Inc.
• Quest Diagnostics Inc.
• Amicus Therapeutics Inc.
• Shire Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Lysosomal Storage Diseases Therapeutics Market is projected to expand from USD 7.69 Billion in 2025 to USD 11.72 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 7.28%. These therapeutics involve specific medical interventions, such as enzyme replacement and substrate reduction therapies, designed to counteract the metabolic deficiencies stemming from lysosomal dysfunction. This market's expansion is primarily fueled by advancements in diagnostic capabilities, including newborn screening, and substantial public-private investments in research for orphan drugs. For instance, the National Institutes of Health allocated approximately $26 million in grants to the Rare Diseases Clinical Research Network in fiscal year 2025, underscoring the significant financial commitment to advance clinical studies for these conditions.

Despite this progress, a considerable hurdle impeding market growth is the exceptionally high cost associated with drug development and the subsequent pressure on pricing. Furthermore, the intricate regulatory environment, coupled with the difficulty of enrolling a sufficient number of participants for clinical trials due to small and geographically dispersed patient populations, creates significant obstacles that can delay the commercial introduction of new therapeutics.

Market Driver

Advancements in enzyme replacement and gene therapies are fundamentally transforming the Global Lysosomal Storage Diseases Therapeutics Market by shifting the clinical focus from mere palliative care to targeted disease modification. Innovative biologics are now engineered with improved cellular uptake mechanisms to more effectively address the underlying metabolic deficiencies of these complex conditions, thereby driving substantial commercial adoption. The commercial impact of these next-generation treatments is clearly reflected in the rapid growth of specialized portfolios; for example, Chiesi Group's Rare Diseases business unit achieved a 31.4% growth rate in the first half of 2025, highlighting the strong demand for its advanced therapeutic solutions.

Concurrently, supportive orphan drug policies and regulatory incentives play a crucial role in sustaining the high-risk development pipelines essential for these niche indications. Government programs offering market exclusivity and accelerated review pathways provide the necessary economic safeguards for biopharmaceutical companies to invest in treatments for limited patient populations. The effectiveness of this supportive framework is evident in regulatory outcomes, with 52% of novel drugs approved by the FDA in 2024 designated for rare diseases. This policy-driven environment directly translates into commercial sustainability, as demonstrated by Amicus Therapeutics reporting third-quarter 2025 total revenue of $169.1 million, confirming the ongoing financial viability of precision medicines in this sector.

Market Challenge

The prohibitive expense of drug development, alongside the inherent difficulties in recruiting an adequate number of participants for clinical trials, acts as a significant constraint on the Global Lysosomal Storage Diseases Therapeutics Market. These financial and logistical barriers escalate the attrition rate of new therapies, as companies face extended timelines and mounting costs to establish safety and efficacy in small, geographically dispersed patient groups. This high-risk environment often discourages sustained investment in all but the most commercially promising candidates, effectively narrowing the pipeline of potential treatments and decelerating the overall pace of market expansion.

The consequences of these hurdles are evident in the substantial gap between identified metabolic deficiencies and available medical interventions. According to the National Organization for Rare Disorders, over 95% of rare diseases still lacked an FDA-approved treatment in 2025. This statistic underscores the severity of the challenge: even with improved diagnostic capabilities, the economic burden of development often prevents the successful commercialization of therapies for the vast majority of these conditions, thereby limiting revenue growth and market maturity within the sector.

Market Trends

A distinct shift toward oral substrate reduction therapies is transforming the treatment landscape by offering a non-invasive alternative to lifelong intravenous infusions. This trend addresses the patient burden by inhibiting the accumulation of toxic substrates through convenient oral dosing, rather than relying exclusively on systemic enzyme replacement. The commercial appeal of this modality is robust; for example, Sanofi reported sales for its oral therapy Cerdelga reached 81 million Euros in Q3 2024, highlighting the sustained market demand for patient-centric delivery mechanisms, particularly in the Gaucher disease segment.

The strategic consolidation of orphan drug pipelines has emerged as a crucial mechanism for ensuring financial sustainability within the high-risk rare disease sector. Biopharmaceutical companies are increasingly assembling diverse portfolios of commercial-stage assets and late-stage candidates to mitigate the volatility associated with dependency on a single product. This diversified approach is yielding measurable stability, as demonstrated by Ultragenyx, which achieved total revenue of 139 million Dollars in Q3 2024, validating the economic strength of a consolidated platform focused on multiple rare metabolic indications.

Key Market Players

• Pfizer, Inc.
• Sanofi SA
• BioMarin Pharmaceutical Inc
• Actelion Ltd.
• Raptor Pharmaceutical Corp.
• Protalix Biotherapeutics Inc.
• Amicus Therapeutics, Inc.
• Quest Diagnostics Inc.
• Amicus Therapeutics Inc.
• Shire Plc

Report Scope

In this report, the Global Lysosomal Storage Diseases Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lysosomal Storage Diseases Therapeutics Market, By Treatment

• Enzyme Replacement Therapy
• Stem Cell Therapy
• Substrate Reduction Therapy
• others

Lysosomal Storage Diseases Therapeutics Market, By Indication

• Gaucher's Disease
• Fabry Disease
• Pompe's Disease
• Mucopolysaccharidosis
• others

Lysosomal Storage Diseases Therapeutics Market, By End User

• Hospitals
• Clinics

Lysosomal Storage Diseases Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lysosomal Storage Diseases Therapeutics Market.

Available Customizations:

Global Lysosomal Storage Diseases Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lysosomal Storage Diseases Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, others)
  • 5.2.2. By Indication (Gaucher's Disease, Fabry Disease, Pompe's Disease, Mucopolysaccharidosis, others)
  • 5.2.3. By End User (Hospitals, Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Lysosomal Storage Diseases Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lysosomal Storage Diseases Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Lysosomal Storage Diseases Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Lysosomal Storage Diseases Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User

7. Europe Lysosomal Storage Diseases Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. France Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Lysosomal Storage Diseases Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. Asia Pacific Lysosomal Storage Diseases Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Lysosomal Storage Diseases Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. Middle East & Africa Lysosomal Storage Diseases Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lysosomal Storage Diseases Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Lysosomal Storage Diseases Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Lysosomal Storage Diseases Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. South America Lysosomal Storage Diseases Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lysosomal Storage Diseases Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Lysosomal Storage Diseases Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Lysosomal Storage Diseases Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lysosomal Storage Diseases Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi SA
• 15.3. BioMarin Pharmaceutical Inc
• 15.4. Actelion Ltd.
• 15.5. Raptor Pharmaceutical Corp.
• 15.6. Protalix Biotherapeutics Inc.
• 15.7. Amicus Therapeutics, Inc.
• 15.8. Quest Diagnostics Inc.
• 15.9. Amicus Therapeutics Inc.
• 15.10. Shire Plc

16. Strategic Recommendations

17. About Us & Disclaimer